Condition 1: End-stage renal disease. Condition 2: Diabetes Mellitus. Condition 3: hemodialysis. Chronic kidney disease, stage 5 Diabetes mellitus due to underlying condition Encounter for adequacy testing for hemodialysis
Conditions
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients 40years and older who have been on Hemodialysis for at least 3 months Patients with diabetes Ability and willingness to collaborate in the study
Exclusion criteria
Exclusion criteria: Patients undergoing Peritoneal Dialysis Taking egg white supplements before entering the study Incomplete completion of questionnaires Individuals who are unable to provide informed consent or participate in quality of life assessments due to cognitive impairment Smoking, alcohol, and hookah use Having allergy to eggs Taking steroidal and non-steroidal anti-inflammatory drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in kidney function markers. Timepoint: At the beginning of the study and 8 weeks after supplementation of EW. Method of measurement: RPeople At the beginning and end of the intervention, after 12 hours of fasting, 5 ml of venous blood samples will be taken from 44 patients. Then, using serum and whole blood samples, we will measure the levels of sodium, phosphorus, potassium, Cr, and uric acid with a kit. Dialysis adequacy (Kt/v) and nPCR will be determined based on urea kinetic modeling.;Inflammatory markers (serum hs-CRP, TNF-a and IL-6). Timepoint: At the beginning of the study and 8 weeks after supplementation of EW. Method of measurement: At the beginning and end of the intervention, 5 ml of venous blood samples will be taken from 44 study participants after 12 hours of fasting. Then, using a combination of serum and whole blood samples, hs-CRP will be measured using immunoturbidimetric method and IL-6, TNF-a will be measured using ELISA kit.;Changes in health-related quality of life. Timepoint: At the beginning of the study and 8 weeks after supplementation of EW. Method of measurement: The quality of life index is measured using the 26-item WHO-QOL BREF questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Glucose level. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: For biochemical indicators, 5 cc of venous blood samples will be taken from 44 patients at the beginning and end of the intervention after 12 hours of fasting. Then, using serum and whole blood samples, fasting blood sugar levels will be measured with a kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ali Tarighat Esfanjani
Tabriz University of Medical Sciences
Outcome results
None listed